저분자 API CDMO 시장 규모, 점유율 및 동향 분석 보고서 : 의약품별, 용도별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

Small Molecule API CDMO Market Summary

The global small molecule API CDMO market size was valued at USD 46.59 billion in 2025 and is projected to reach USD 80.74 billion by 2033, growing at a CAGR of 7.28% from 2026 to 2033. The market is experiencing growth driven by rising demand for complex APIs and advanced manufacturing capabilities, increasing geopolitical shifts and supply chain resilience initiatives, sustainability, and rising green chemistry adoption, and increasing digitalization, AI integration, and regulatory evolution.

The increasing complexity of small-molecule APIs, including multi-step synthesis, chiral chemistry, and high-potency compounds, is driving demand for specialized CDMO capabilities. Pharmaceutical companies are outsourcing in large numbers to partners with advanced manufacturing expertise, containment infrastructure, and regulatory-compliant facilities. This is particularly evident in the growing pipeline of highly potent APIs (HPAPIs) and complex small molecules used in oncology and targeted therapies. In addition, the growing demand for innovative therapies is accelerating the need for CDMOs equipped with high-containment technologies and specialized process development capabilities. As drug molecules become more structurally sophisticated, CDMOs offering integrated services from early-stage development to commercial-scale manufacturing are gaining a competitive edge.

In addition, global geopolitical changes are transforming pharmaceutical supply chains, driving greater emphasis on resilience, localization, and supply security. Governments are introducing legislative measures to reduce dependency on foreign API sources, particularly in critical drug categories. For instance, the Biosecure Act, passed in September 2024 in the U.S., is encouraging domestic manufacturing of essential drugs, creating new opportunities for CDMOs with a strong regional presence or the ability to comply with stringent sourcing requirements. This shift is prompting pharmaceutical companies to diversify suppliers and invest in regionally aligned CDMO partnerships. In addition, enhanced quality systems and regulatory compliance frameworks are becoming essential to ensure uninterrupted supply.

Furthermore, sustainability is emerging as a critical driver in the market, influenced by both regulatory pressures and evolving customer expectations. Pharmaceutical companies are prioritizing environmentally responsible manufacturing practices, including green chemistry, waste reduction, and energy-efficient processes. The regulatory bodies across regions are implementing stricter environmental guidelines, compelling CDMOs to adopt sustainable technologies and reduce their carbon footprint. This includes the use of safer solvents, continuous manufacturing techniques, and improved process efficiency to minimize environmental impact. In addition, clients are selecting CDMO partners based on their sustainability credentials, making it a key differentiator in competitive bidding.

Global Small Molecule API CDMO Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global small molecule API CDMO market report based on drug, application, end use, and region:

• Drug Outlook (Revenue, USD Million, 2021 - 2033)
• Innovators
• Generics
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Cardiovascular Diseases
• Oncology
• Respiratory Disorders
• Neurology
• Metabolic Disorders
• Infectious Diseases
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Pharmaceutical
  • Small
  • Medium
  • Large
• Biotechnology
  • Small
  • Medium
  • Large
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Oman
  • Qatar

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Drug
  • 1.2.2. Application
  • 1.2.3. End Use
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information Or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
  • 1.7.2. Top-Down Analysis
  • 1.7.3. Bottom-Up Approach
  • 1.7.4. Multivariate Analysis
• 1.8. List of Secondary Sources
• 1.9. List of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Small Molecule API CDMO Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing Demand for Small Molecule Drugs
    • 3.2.1.2. Increasing Outsourcing Trends Among Pharmaceutical Companies
    • 3.2.1.3. Surge in Number of Clinical Trials
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Compliance Issues While Outsourcing
    • 3.2.2.2. Changing Scenarios in Developing Economies
• 3.3. Technology Landscape
• 3.4. Pricing Model Analysis
• 3.5. Tariff Impact Analysis
• 3.6. Value Chain Analysis
  • 3.6.1. Supply Trends
  • 3.6.2. Demand Trends
• 3.7. Market Analysis Tools
  • 3.7.1. Porter's Five Force Analysis
  • 3.7.2. PESTEL by SWOT Analysis

Chapter 4. Small Molecule API CDMO Market: Drug Estimates & Trend Analysis

• 4.1. Small Molecule API CDMO Market, By Drug: Segment Dashboard
• 4.2. Small Molecule API CDMO Market, By Drug: Movement Analysis
• 4.3. Small Molecule API CDMO Market Estimates & Forecasts, By Drug, 2021 - 2033
• 4.4. Innovators
  • 4.4.1. Innovators Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Generics
  • 4.5.1. Generics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Small Molecule API CDMO Market: Application Estimates & Trend Analysis

• 5.1. Small Molecule API CDMO Market, By Application: Segment Dashboard
• 5.2. Small Molecule API CDMO Market, By Application: Movement Analysis
• 5.3. Small Molecule API CDMO Market Estimates & Forecasts, By Application, 2021 - 2033
• 5.4. Cardiovascular Diseases
  • 5.4.1. Cardiovascular Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Oncology
  • 5.5.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Respiratory Disorders
  • 5.6.1. Respiratory Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.7. Neurology
  • 5.7.1. Neurology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.8. Metabolic Disorders
  • 5.8.1. Metabolic Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.9. Infectious Diseases
  • 5.9.1. Infectious Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.10. Others
  • 5.10.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Small Molecule API CDMO Market: End Use Estimates & Trend Analysis

• 6.1. Small Molecule API CDMO Market, By End Use: Segment Dashboard
• 6.2. Small Molecule API CDMO Market, By End Use: Movement Analysis
• 6.3. Small Molecule API CDMO Market Estimates & Forecasts, By End Use, 2021 - 2033
• 6.4. Pharmaceutical
  • 6.4.1. Pharmaceutical Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.2. Small
    • 6.4.2.1. Small Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.3. Medium
    • 6.4.3.1. Medium Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.4. Large
    • 6.4.4.1. Large Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Biotechnology
  • 6.5.1. Biotechnology Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.2. Small
    • 6.5.2.1. Small Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.3. Medium
    • 6.5.3.1. Medium Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.4. Large
    • 6.5.4.1. Large Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Small Molecule API CDMO Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Dashboard
• 7.2. Regional Market Share Analysis, 2025 & 2033
• 7.3. North America
  • 7.3.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.2. U.S
    • 7.3.2.1. Key Country Dynamics
    • 7.3.2.2. Competitive Scenario
    • 7.3.2.3. Regulatory Framework
    • 7.3.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.3. Canada
    • 7.3.3.1. Key Country Dynamics
    • 7.3.3.2. Competitive Scenario
    • 7.3.3.3. Regulatory Framework
    • 7.3.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.4. Mexico
    • 7.3.4.1. Key Country Dynamics
    • 7.3.4.2. Competitive Scenario
    • 7.3.4.3. Regulatory Framework
    • 7.3.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.4. Europe
  • 7.4.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.2. UK
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Competitive Scenario
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.3. Germany
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Competitive Scenario
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.4. France
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Competitive Scenario
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.5. Italy
    • 7.4.5.1. Key Country Dynamics
    • 7.4.5.2. Competitive Scenario
    • 7.4.5.3. Regulatory Framework
    • 7.4.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.6. Spain
    • 7.4.6.1. Key Country Dynamics
    • 7.4.6.2. Competitive Scenario
    • 7.4.6.3. Regulatory Framework
    • 7.4.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.7. Denmark
    • 7.4.7.1. Key Country Dynamics
    • 7.4.7.2. Competitive Scenario
    • 7.4.7.3. Regulatory Framework
    • 7.4.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.8. Sweden
    • 7.4.8.1. Key Country Dynamics
    • 7.4.8.2. Competitive Scenario
    • 7.4.8.3. Regulatory Framework
    • 7.4.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.9. Norway
    • 7.4.9.1. Key Country Dynamics
    • 7.4.9.2. Competitive Scenario
    • 7.4.9.3. Regulatory Framework
    • 7.4.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.2. Japan
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.3. China
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.4. India
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Competitive Scenario
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.5. Thailand
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Competitive Scenario
    • 7.5.5.3. Regulatory Framework
    • 7.5.5.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.6. South Korea
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Competitive Scenario
    • 7.5.6.3. Regulatory Framework
    • 7.5.6.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.7. Australia
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Competitive Scenario
    • 7.5.7.3. Regulatory Framework
    • 7.5.7.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Latin America
  • 7.6.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.2. Brazil
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.3. Argentina
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. MEA
  • 7.7.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.2. South Africa
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Competitive Scenario
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.3. Saudi Arabia
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Competitive Scenario
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.4. UAE
    • 7.7.4.1. Key Country Dynamics
    • 7.7.4.2. Competitive Scenario
    • 7.7.4.3. Regulatory Framework
    • 7.7.4.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.5. Kuwait
    • 7.7.5.1. Key Country Dynamics
    • 7.7.5.2. Competitive Scenario
    • 7.7.5.3. Regulatory Framework
    • 7.7.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.6. Oman
    • 7.7.6.1. Key Country Dynamics
    • 7.7.6.2. Competitive Scenario
    • 7.7.6.3. Regulatory Framework
    • 7.7.6.4. Oman Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.7. Qatar
    • 7.7.7.1. Key Country Dynamics
    • 7.7.7.2. Competitive Scenario
    • 7.7.7.3. Regulatory Framework
    • 7.7.7.4. Qatar Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Key Participant Categorization
  • 8.1.1. Market Leaders
  • 8.1.2. Emerging Players
• 8.2. Market Share/Assessment Analysis, 2025 (Heat Map Analysis)
• 8.3. Company Profiles
  • 8.3.1. Lonza Group
    • 8.3.1.1. Company Overview
    • 8.3.1.2. Financial Performance
    • 8.3.1.3. Service Benchmarking
    • 8.3.1.4. Strategic Initiatives
  • 8.3.2. Catalent
    • 8.3.2.1. Company Overview
    • 8.3.2.2. Financial Performance
    • 8.3.2.3. Service Benchmarking
    • 8.3.2.4. Strategic Initiatives
  • 8.3.3. Thermo Fisher Scientific
    • 8.3.3.1. Company Overview
    • 8.3.3.2. Financial Performance
    • 8.3.3.3. Service Benchmarking
    • 8.3.3.4. Strategic Initiatives
  • 8.3.4. WuXi AppTec
    • 8.3.4.1. Company Overview
    • 8.3.4.2. Financial Performance
    • 8.3.4.3. Service Benchmarking
    • 8.3.4.4. Strategic Initiatives
  • 8.3.5. Siegfried Holding AG
    • 8.3.5.1. Company Overview
    • 8.3.5.2. Financial Performance
    • 8.3.5.3. Service Benchmarking
    • 8.3.5.4. Strategic Initiatives
  • 8.3.6. Cambrex Corporation
    • 8.3.6.1. Company Overview
    • 8.3.6.2. Financial Performance
    • 8.3.6.3. Service Benchmarking
    • 8.3.6.4. Strategic Initiatives
  • 8.3.7. Recipharm
    • 8.3.7.1. Company Overview
    • 8.3.7.2. Financial Performance
    • 8.3.7.3. Service Benchmarking
    • 8.3.7.4. Strategic Initiatives
  • 8.3.8. CordenPharma
    • 8.3.8.1. Company Overview
    • 8.3.8.2. Financial Performance
    • 8.3.8.3. Service Benchmarking
    • 8.3.8.4. Strategic Initiatives
  • 8.3.9. Ajinomoto Bio-Pharma Services
    • 8.3.9.1. Company Overview
    • 8.3.9.2. Financial Performance
    • 8.3.9.3. Service Benchmarking
    • 8.3.9.4. Strategic Initiatives
  • 8.3.10. Curia
    • 8.3.10.1. Company Overview
    • 8.3.10.2. Financial Performance
    • 8.3.10.3. Service Benchmarking
    • 8.3.10.4. Strategic Initiatives
  • 8.3.11. Piramal Pharma Solutions
    • 8.3.11.1. Company Overview
    • 8.3.11.2. Financial Performance
    • 8.3.11.3. Service Benchmarking
    • 8.3.11.4. Strategic Initiatives
  • 8.3.12. Jubilant Biosys
    • 8.3.12.1. Company Overview
    • 8.3.12.2. Financial Performance
    • 8.3.12.3. Service Benchmarking
    • 8.3.12.4. Strategic Initiatives
  • 8.3.13. Syngene International
    • 8.3.13.1. Company Overview
    • 8.3.13.2. Financial Performance
    • 8.3.13.3. Service Benchmarking
    • 8.3.13.4. Strategic Initiatives
  • 8.3.14. Neuland Laboratories
    • 8.3.14.1. Company Overview
    • 8.3.14.2. Financial Performance
    • 8.3.14.3. Service Benchmarking
    • 8.3.14.4. Strategic Initiatives
  • 8.3.15. Axplora
    • 8.3.15.1. Company Overview
    • 8.3.15.2. Financial Performance
    • 8.3.15.3. Service Benchmarking
    • 8.3.15.4. Strategic Initiatives